Genmab buys ADC technology license from Synaffix

Genmab will pay USD 4.5m upfront for access to antibody technologies developed by Synaffix, in a deal that could total up to USD 415m.
Photo: Tuala Hjarnø / Genmab / PR
Photo: Tuala Hjarnø / Genmab / PR
by mikkel aabenhus hemmingsen, translated by catherine brett

A new licensing agreement will secure Genmab the right to use technologies developed by Dutch biotech company Synaffix.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading